Phil Ebeling is a medical device executive with substantial experience in operations and new product development. He currently serves on the Advisory Council for Graham Partners’ portfolio company, Teamvantage.

Phil previously worked for Abbott Laboratories (formerly St. Jude Medical) as VP, Chief Technology Officer – Cardiovascular and Neuromodulation Division following the sale of St. Jude Medical to Abbott. Phil was responsible for an organization of 1300 R&D employees at 19 global locations. He was also responsible for 250 regulatory affairs personnel, while leading critical new technology discussions with FDA and various, global notified bodies. His division had its own technology development, including electrical and non-electrical human implantables (Class III devices), and various engineering disciplines (Software, Hardware, Firmware, Electrical, and Biomedical). Prior to that he held the role of Senior Vice President, R&D – Cardiovascular and Electrophysiology Division (CATD). Prior to joining St. Jude Medical in 2008, he spent over 12 years at Boston Scientific where he held numerous positions starting as an engineer and ultimately becoming their Director of Program Management and Risk Management. Prior to Boston Scientific, he worked at Rexam Flexible Packaging in product development and engineering.

Phil has a Bachelor of Science, Chemical Engineering from the University of Minnesota and a Master’s in Business Administration from the University of St. Thomas. He also completed the Advanced Management Program at Harvard Business School. He is a member of the National Society of Professional Engineers and holds patents relating to Multi-Cord Extrusion Manufacturing Techniques for Catheter Members, Chemical Bonding Technique for Angioplasty Catheter Assembly Operations and Procedural Sheath Adapter for Vascular Closure Device.